Abstract The retinoblastoma (Rb) tumor suppressor gene is frequently inactivated in cancer, resulting in deregulated activation of E2F transcription factors, which promote S-phase entry, p53-dependent and p53-independent apoptosis. Transformed cells evade p53-dependent apoptosis initiated by Rb inactivation by TP53 mutation. However, the mechanisms by which cancer cells circumvent p53-independent apoptosis in this context are poorly understood. Because Rb inactivation primes cells for apoptosis by p53-independent induction of procaspases, we postulated that aB-crystallin, an inhibitor of procaspase-3 activation, would suppress caspase activation in cells with combined Rb and p53 inactivation. Notably, aB-crystallin is commonly expressed in ER/PR/HER2 ''triple-negative'' breast carcinomas characterized by frequent Rb loss and TP53 mutation. We report that aB-crystallin -/-knock out (KO) MEFs immortalized by dominant negative (DN) p53 are resistant to transformation by the adenovirus E1A oncoprotein, which inactivates Rb, while wild-type (WT) MEFs are readily transformed by DN p53 and E1A. aBcrystallin -/-KO MEFs stably expressing DN p53 and E1A were more sensitive to chemotherapy-induced caspase-3 activation and apoptosis than the corresponding WT MEFs, despite comparable induction of procaspases by E1A. Similarly, silencing Rb in WT and aB-crystallin -/-KO MEFs immortalized by DN p53 increased procaspase levels and sensitized aB-crystallin -/-KO MEFs to chemotherapy. Furthermore, silencing aB-crystallin in triplenegative breast cancer cells, which lack Rb and express mutant p53, enhanced chemotherapy sensitivity compared to non-silencing controls. Our results indicate that aBcrystallin inhibits caspase activation in cells primed for apoptosis by Rb inactivation and plays a novel oncogenic role in the context of combined Rb and p53 inactivation.
Introduction
The Rb tumor suppressor gene product functions as a transcriptional corepressor, which binds to members of the E2F family of transcription factors and inhibits E2F-dependent transactivation of genes promoting S-phase entry and apoptosis induction [1, 2] . Rb inactivation releases E2F from the Rb-E2F complex and promotes cell proliferation and apoptosis. Inactivation of Rb promotes p53-dependent apoptosis by transcriptional activation of Apaf-1, which is required for procaspase-9 activation in the intrinsic apoptotic pathway, and p53-independent apoptosis by E2F-dependent transcription of procaspases, which ''primes'' cells for apoptosis induction by lowering the threshold for caspase activation [3, 4] . The apoptosissensitizing effect of Rb inactivation in cancer cells is frequently counteracted by mutational inactivation of TP53 [1, 2] . Oncogenic transformation by tumor viruses requires inactivation of both Rb and p53 and is accomplished by the adenovirus E1A and E1B oncoproteins or papillomavirus E7 and E6 oncoproteins, respectively [5] [6] [7] [8] . Moreover, Rb gene loss or diminished expression of Rb is frequently accompanied by TP53 mutation in human tumors, including clinically aggressive ''triple-negative'' breast carcinomas, which lack expression of the hormone receptors ER, PR, and HER2/ErbB2 [9] [10] [11] [12] [13] . These findings suggest that TP53 mutation cooperates with Rb loss to transform epithelial cells by suppressing p53-dependent apoptosis.
In contrast to p53-dependent apoptosis, the mechanisms by which transformed cells suppress p53-independent apoptosis initiated by Rb inactivation are poorly understood. Rb loss or inactivation by the adenovirus E1A oncoprotein, which dissociates the Rb-E2F complex, results in E2F-dependent transcriptional activation of procaspases [4, 5] . The accumulation of procaspases primes cells for cell death by sensitizing them to apoptotic stimuli. We postulated that the molecular chaperone aB-crystallin, which inhibits apoptosis by suppressing procaspase-3 activation [14] [15] [16] , might inhibit caspase activation in cells primed for apoptosis by Rb inactivation. Caspase-3 is an effector caspase that executes cell death by cleaving key cellular proteins [17] . Notably, aB-crystallin is commonly expressed in triple-negative breast carcinomas, which frequently harbor Rb gene deletion/reduced Rb expression and TP53 mutations [9] [10] [11] [12] [13] 18] .
Here, we report that aB-crystallin -/-knock out (KO) MEFs immortalized by dominant negative (DN) p53 are resistant to transformation by E1A, while wild-type (WT) MEFs are transformed by DN p53 and E1A. Deletion of aB-crystallin sensitizes MEFs stably expressing DN p53 and E1A to chemotherapy-induced caspase-3 activation and apoptosis. Similarly, silencing Rb in DN p53-immortalized WT and aB-crystallin -/-KO MEFs increased procaspase levels and enhanced the sensitivity of aB-crystallin -/-KO MEFs to chemotherapy. Moreover, siRNAs targeting aB-crystallin augmented chemotherapy-induced apoptosis in triple-negative breast cancer cells, which lack Rb and express a mutant p53 protein.
Our findings indicate that aB-crystallin inhibits caspase activation in cells primed for apoptosis by Rb inactivation and counteracts p53-independent apoptosis in this context.
Methods

Isolation of MEFs
aB-Crystallin
-/-KO mice containing a deletion of aBcrystallin and the adjacent HspB2 gene were described [19] . MEFs were obtained from 13.5-day aB-crystallin ?/?
WT and aB-crystallin -/-KO embryos as described [20] and grown DMEM supplemented with 10 % FCS, 100 IU/ml penicillin, 100 lg/ml streptomycin, 2 mM L-glutamine, and 0.1 mM MEM nonessential amino acids (Life Technologies). Animal experiments were approved by the Animal Care and Use Committee.
Retroviral infection
Retroviruses were produced in Phoenix-Eco and PhoenixAmpho cells and used to infect MEFs as described [21] . Phoenix cells (2.5 9 10 6 ) were transfected with 5 lg pBABE-Puro-DN p53 (GSE56), pLXSN-E1A, pLXSN-HRasV12 or empty vector using Lipofectamine 2000 (Life Technologies) and grown in DMEM containing 10 % FCS, 100 IU/ml penicillin, and 100 lg/ml streptomycin. Filtered retroviral supernatant was supplemented with 10 lg/ml polybrene (Millipore) and used to infect 3 9 10 5 MEFs, which were selected for growth in Puromycin (1 lg/ml, Sigma) and/or Geneticin (4 mg/ml, Life Technologies).
Immunoblotting
Immunoblotting was performed as described [22] with antibodies against aB-crystallin (StressGen), a-tubulin, b-actin (Sigma), p53, procaspase-3, procaspase-9, procaspase-6, p780 Rb, p15, cyclin B1, Cdk4, cyclin D1, cyclin D2, cyclin D3 (Cell Signaling), E1A (Neomarkers), and total Rb (Santa Cruz Biotechnology).
Cell growth assays 5 9 10 4 MEFs were plated and grown as described under ''Isolation of wild-type and aB-crystallin -/-knock out MEFs''. Viable cells were scored by trypan blue (Life Technologies) exclusion. Population doubling after each passage was calculated using the formula: log[(cell number after 3 days of growth)/(5 9 10 4 )]/log 2 as described [23, 24] . The total cell number at the end of each passage was determined using the formula: passage (n ? 1) = passage (n) 9 2 (n?1)population doubling .
Senescence-associated b-galactosidase staining Cells were fixed with 2 % formaldehyde/0.2 % glutaraldehyde and stained with X-Gal. Micrographs of b-galactosidase-stained MEFs were taken using an Axioplan 2 microscope (Carl Zeiss).
BrdU incorporation
Subconfluent cells were incubated with 10 lM BrdU (Sigma) for 1 h. Cells were then fixed with methanol, incubated with 0.01 % Triton X-100, and subjected to immunofluorescence [24] using a BrdU antibody (Sigma). BrdU positive cells were detected with an AxioVision fluorescence microscope (Carl Zeiss).
Cell cycle analyses
Cell cycle profiles were determined by flow cytometry analysis of DNA content. Cells were fixed in 70 % ethanol for 2 h at 4°C, incubated with 40 lg/ml propidium iodide and 100 lg/ml RNase A (Sigma) for 1 h at 37°C, and analyzed using an EPICS Elite ESP Cell Sorter (Beckman Coulter).
Apoptosis assays
Cells were incubated with vehicle, doxorubicin or Taxol (Sigma) for 24 h. Apoptotic cells were scored using an Annexin V-FITC Apoptosis Detection kit (BD Biosciences) using in Epics XL-MCL Flow Cytometer (Beckman Coulter) and FlowJo software.
Matrigel invasion
Serum-starved cells (1 9 10 5 ) were seeded onto the upper surface of transwell chamber inserts coated with Matrigel (BD Biosciences) in serum-free DMEM. 10 % FCS was added to the lower compartment as a chemoattractant. After 24 h, the cells on the lower surface of the filter were stained with 1 % crystal violet (Sigma) and scored in 10 randomly selected fields.
Soft agar assay Cells (1.5 9 10 5 ) were plated in 0.7 % agarose (BD Biosciences) on a cell-free 1.4 % agarose bed. Colonies [100 lm in size were scored after 2 weeks in 10 randomly selected fields.
Caspase-3 activity assay Cells were treated with 250 nM Doxorubicin or 125 nM Taxol for 12 h, and caspase-3 activity was measured with a Caspase 3 Colorimetric Assay Kit (Sigma). Cell lysates were incubated with 20 mM Ac-DEVD-pNA, and the absorbance at 405 nm was measured.
Lentiviral Rb shRNA
Lentiviruses expressing pGIPZ-murine Rb shRNA (OpenBioSystems) were produced by co-transfecting 293 T cells with 5 lg ViraPower mix, and 2 lg non-silencing control vector or murine Rb shRNA using Lipofectamine 2000. Filtered viral supernatant was supplemented with 10 lg/ml polybrene and applied to MEFs.
aB-Crystallin siRNAs
Human MDA-MB-468 triple-negative breast cancer cells (ATCC) were grown in DMEM supplemented with 10 % FCS, 100 IU/ml penicillin, and 100 lg/ml streptomycin. MDA-MB-468 cells were transfected with a pool of siRNA duplexes specific to human aB-crystallin mRNA (100 nM, Dharmacon Research) using Lipofectamine 2000 reagent. Seventy-two hours after transfection, cells were lysed for immunoblotting or treated with chemotherapy.
Statistical analysis
We used the Microsoft Excel program to calculate the SD and statistical significance between samples using the Student's t test.
Results
Functional inactivation of p53 immortalizes WT and aB-crystallin
-/-KO MEFs aB-Crystallin -/-KO MEFs did not express detectable levels of aB-crystallin protein as determined by immunoblotting (Fig. 1a) . In contrast, WT MEFs and human mammary epithelial cells (HMECs) expressed aB-crystallin. To inactivate p53, we retrovirally transduced WT and aB-crystallin -/-KO MEFs with a truncated GSE56 p53 cDNA lacking the p53 transactivation domain, which acts as a dominant negative (DN) inhibitor of WT p53 by binding/stabilizing the WT protein and disrupting its transcriptional activity [25] . Consistent with prior reports [25] , stable overexpression of DN p53 in WT and aB-crystallin -/-KO MEFs (abbreviated WT DN p53 MEFs and KO DN p53 MEFs, respectively) resulted in a striking accumulation of endogenous p53 protein (Fig. 1b) , which is functionally inactive because these MEFs fail to undergo p53-dependent senescence as determined by senescenceassociated b-galactosidase expression (Fig. 1c) . These findings indicate that functional inactivation of p53 immortalizes WT and aB-crystallin -/-KO MEFs.
aB-Crystallin inhibits cell growth and cell cycle progression in MEFs immortalized by p53 inactivation
To determine the growth rate of immortalized WT and aBcrystallin -/-KO DN p53 MEFs, we measured the doubling rate at each passage by plating 5 9 10 4 MEFs and counting the number of viable cells after 3 days of growth (Fig. 2a) . KO DN p53 MEFs grew more rapidly than WT DN p53 MEFs under normal growth conditions and the differences in growth rates were enhanced with increasing passages. Importantly, WT MEFs immortalized by DN p53 did not express HspB2 ( Supplementary Fig. 1 ), the adjacent gene co-deleted in the aB-crystallin -/-KO MEFs [19] , indicating that the observed effects were specifically due to aB-crystallin deletion. These findings demonstrate that aB-crystallin inhibits the growth of MEFs immortalized by p53 inactivation.
To determine the role of aB-crystallin in DNA replication in MEFs immortalized by p53 inactivation, WT and KO DN p53 MEFs were grown in media containing 10 or 0.1 % FCS for 72 h, and the percentage of BrdU positive cells was determined (Fig. 2b) . Although the percentage of BrdU positive cells was similar when MEFs were grown in 10 % FCS, KO DN p53 MEFs exhibited a greater percentage of BrdU positive cells than WT DN p53 MEFs when these MEFs were grown in 0.1 % FCS. These findings indicate that aB-crystallin inhibits DNA replication during S-phase in MEFs immortalized by p53 inactivation.
To evaluate the role of aB-crystallin in cell cycle progression in MEFs immortalized by p53 inactivation, WT and KO DN p53 MEFs were grown in media containing 0.1 % FCS for 72 h and then analyzed for DNA content by flow cytometry. KO DN p53 MEFs had a greater percentage of cells in S and G2 phase and reduced percentage of cells in G1 compared to WT DN p53 MEFs when grown in 0.1 % FCS (Fig. 2c) . Of note, the lack of significant differences in BrdU positive cells between WT and KO DN p53 MEFs grown in 10 % FCS may reflect that fact that these cells were not synchronized, while growth in 0.1 % FCS likely synchronized the cells. Collectively, these results indicate that aB-crystallin inhibits cell growth and S-phase entry in MEFs immortalized by p53 inactivation.
We next examined WT and KO DN p53 MEFs grown in media supplemented with 10 or 0.1 % FCS for expression of genes regulating S-phase entry and cell cycle progression by immunoblotting (Fig. 2d) . KO DN p53 MEFs showed higher expression levels of Ser 780 phosphorylated Rb protein (p780 Rb) compared to WT DN p53 MEFs, whereas total Rb protein levels were similar. In addition, cyclin B1 levels were increased in KO DN p53 MEFs compared to WT DN p53 MEFs grown in 0.1 % FCS (but not 10 % FCS). No other consistent pattern of differential expression of other cell cycle regulators was observed between WT and KO DN p53 MEFs. Because phosphorylation of Rb is an essential step in the initiation of transcription of many genes required for S-phase entry and cell cycle progression [26] , our findings suggest that the growth-inhibiting effects of aB-crystallin in MEFs immortalized by p53 inactivation may be due to diminished phosphorylation of Rb, while reduced cyclin B1 levels may also contribute to the observed growth inhibition in 0.1 % FCS. Primary rodent cells are readily transformed by p53 inactivation in combination with a second oncogenic alteration such as ectopic expression of the E1A or H-RasV12 oncogene [6, 27] . To examine the role of aBcrystallin in oncogenic transformation, we retrovirally transduced immortalized WT and aB-crystallin -/-KO DN p53 MEFs with E1A or H-RasV12 cDNA (or empty vector). In striking contrast to the growth-inhibiting effects of aB-crystallin in MEFs immortalized by p53 inactivation, WT DN p53 MEFs stably expressing E1A (abbreviated WT E1A DN p53 MEFs) grew more rapidly than the corresponding KO E1A DN p53 MEFs (Fig. 3a) . Intriguingly, WT E1A DN p53 MEFs formed colonies in soft agar and exhibited anchorage-independent growth, a hallmark of oncogenic transformation, while KO E1A DN p53 MEFs were largely unable to grow in soft agar (Fig. 3b) . In contrast, deletion of aB-crystallin did not affect anchorage-independent growth of MEFs transformed by the combination of DN p53 and H-RasV12. Consistent with their transformed phenotype, WT E1A DN p53 MEFs invaded through Matrigel-occluded pores in a transwell invasion chamber, while KO E1A DN p53 MEFs were largely unable to invade in this assay (Fig. 3c) . Notably, WT MEFs stably expressing DN p53 and E1A did not express HspB2 (Supplementary Fig. 1 ) and were therefore unaffected by co-deletion of this adjacent gene. These observations suggest that aB-crystallin plays an essential and previously unrecognized role in oncogenic transformation by E1A overexpression in the setting of p53 inactivation. 3 aB-Crystallin is required for oncogenic transformation by E1A and inhibits the apoptosis-sensitizing effects of E1A. a WT and aB-crystallin -/-KO MEFs stably expressing DN p53 and E1A (abbreviated WT E1A DN p53 and KO E1A DN p53) were grown in subconfluent culture with the indicated passage (p) number reflecting 3-day growth periods (mean ± SD, n = 3). b WT E1A DN p53 MEFs and aB-crystallin -/-KO E1A DN p53 MEFs were grown in soft agar for 2 weeks and the number of colonies was scored (mean ± SD, n = 3). WT and aB-crystallin -/-KO DN p53 MEFs stably expressing H-RasV12 oncogene were also analyzed. c WT and aB-crystallin -/-KO E1A DN p53 MEFs were examined for transwell invasion through Matrigel-occluded pores using 10 % FCS as a chemoattractant. Invading cells were visualized by crystal violet staining and scored (mean ± SD, n = 3). d Immortalized WT and aB-crystallin -/-KO DN p53 MEFs were acutely infected with a retrovirus expressing E1A and the percentage of Annexin V-positive MEFs was determined by flow cytometry (mean ± SD, n = 3). e and f WT E1A DN p53 MEFs and aB-crystallin -/-KO E1A DN p53 MEFs were treated with 250 nM Taxol (e) or 1 lM Doxorubicin (Dox) (f) for 24 h and the percentage of Annexin V-positive cells was determined (mean ± SD, n = 3). *P \ 0.05, **P \ 0.01, or ***P \ 0.001 versus control WT E1A DN p53 MEFs Given the well-established role of aB-crystallin in suppressing apoptosis by inhibiting caspase-3 activation [14] [15] [16] , we examined whether aB-crystallin deletion sensitized MEFs to apoptosis. Acute infection of immortalized WT and KO DN p53 MEFs with E1A expressing retroviruses did not result in apoptosis induction compared to MEFs infected with control empty vector retroviruses (Fig. 3d) , indicating that E1A overexpression is not sufficient to induce apoptosis. Because E1A has been shown to sensitize cancer cells to a variety of chemotherapy drugs, including paclitaxel (Taxol) and Doxorubicin [28, 29] , we treated WT and KO E1A DN p53 MEFs with vehicle, Taxol (250 nM) or Doxorubicin (1 lM) for 24 h and measured the percentage of Annexin V-positive cells by flow cytometry (Fig. 3e, f) . KO E1A DN p53 MEFs were more sensitive to apoptosis induction by Taxol and Doxorubicin than WT E1A DN p53 MEFs. These findings indicate that aB-crystallin inhibits the apoptosis-sensitizing effects of E1A. Moreover, these data suggest that aBcrystallin plays a key role in oncogenic transformation by E1A by counteracting its apoptosis-sensitizing effects.
aB-Crystallin inhibits E1A-induced caspase-3 activation in response to chemotherapy drugs
Rb inactivation by a variety of mechanisms, including E1A overexpression, leads to an accumulation of free E2F1 and transactivation of E2F-responsive apoptotic genes, including procaspases, resulting in enhanced sensitivity to apoptotic stimuli or ''apoptotic priming'' [4, 30] . We postulated that aB-crystallin would inhibit caspase activation in MEFs primed for apoptosis by E1A. Consistent with these reports, E1A overexpression in WT and KO DN p53 MEFs resulted in increased Ser 780 phosphorylated Rb (inactivated) and elevated levels of procaspases-3, -6, and -9 (Fig. 4a) . KO E1A DN p53 MEFs that were primed for apoptosis by elevated procaspase levels were more sensitive to Taxol-and Doxorubicin-induced caspase-3 activation than WT E1A DN p53 MEFs as determined by a colorimetric DEVDase activity assay (Fig. 4b, c) . Collectively, these data indicate that aB-crystallin inhibits caspase activation in cells primed for apoptosis by E1A.
aB-Crystallin inhibits the apopotosis-sensitizing effects of Rb silencing
To determine whether the observed apoptosis-sensitizing effects of E1A were indeed due to inactivation of Rb, we stably silenced Rb in immortalized WT and KO DN p53 MEFs using a retroviral shRNA targeting murine Rb (Fig. 5a ). Both WT and KO DN p53 MEFs stably expressing shRb had diminished levels of Rb protein by immunoblotting compared with WT and KO DN p53
MEFs stably expressing a non-silencing control construct. Moreover, Rb silencing augmented procaspase-3 levels. Treatment of WT and KO DN p53 shRb MEFs with Taxol or Doxorubicin resulted in an increased cell death in KO DN p53 shRb MEFs compared to their WT counterparts as determined by Annexin V labeling (Fig. 5b) . These data indicate that Rb RNAi phenocopies the apoptosis-sensitizing effects of E1A in MEFs harboring p53 inactivation, thereby confirming that Rb is the relevant molecular target responsible for the observed effects.
To validate our observations in cancer cells, we chose human MDA-MB-468 triple-negative breast cancer cells, which lack Rb expression and have a TP53 mutation [31, 32] . Immunoblot analysis confirmed that MDA-MB-468 cells lack detectable Rb protein (Fig. 5c) . To evaluate the role of aB-crystallin in apoptosis induction in this model, we transfected MDA-MB-468 cells with either nonsilencing control siRNAs or a pool of aB-crystallin siRNAs. The aB-crystallin siRNA pool robustly reduced the levels of aB-crystallin in MDA-MB-468 cells compared to that observed in cells transfected with non-silencing control siRNAs (Fig. 5d) . Treatment of aB-crystallin siRNAtransfected MDA-MB-468 cells with Taxol or Doxorubicin resulted in greater cell death than in non-silencing control siRNA transfected cells as determined by Annexin V labeling (Fig. 5e) . These data indicate aB-crystallin inhibits chemotherapy-induced apoptosis in an established human triple-negative breast cancer cell line with TP53 mutation and Rb loss.
Discussion
The Rb tumor suppressor gene is frequently inactivated in cancer, resulting in dysregulated E2F activity and transcriptional induction of genes, which promote S-phase entry as well as p53-dependent and p53-independent apoptosis [1, 2] . Transformed cells frequently evade p53-dependent apoptosis initiated by Rb inactivation via mutational inactivation of TP53, thereby accounting for the cooperativity of Rb and p53 inactivation in oncogenic transformation, the coordinated inactivation of Rb and p53 by tumor viruses, and the frequent association of Rb gene loss/reduced Rb expression and TP53 mutation in human tumors [1, 2, [10] [11] [12] . However, the mechanisms by which tumors suppress p53-independent apoptosis in the setting of Rb inactivation are largely unknown. Rb inactivation promotes p53-independent cell death via E2F-depedendent transcription of procaspases [4] . The accumulation of procaspases primes cells for apoptosis by lowering the threshold for stress-induced caspase activation.
We have demonstrated that the antiapoptotic molecular chaperone aB-crystallin, previously reported to inhibit procaspase-3 activation [14] [15] [16] , is a novel negative regulator of p53-independent apoptosis initiated by Rb inactivation. Several lines of evidence support this conclusion. First, aB-crystallin -/-KO MEFs stably expressing DN p53 and E1A were more sensitive to caspase-3 activation and apoptosis induction by chemotherapy than WT MEFs stably expressing DN p53 and E1A, even though the induction of procaspase levels by E1A was comparable in both models. Importantly, WT E1A DN p53 MEFs did not express HspB2, the adjacent gene co-deleted in the aBcrystallin -/-KO MEFs [19] , indicating that the observed effects were specifically due to aB-crystallin deletion. Second, stably silencing Rb with a shRNA in WT and aBcrystallin -/-KO MEFs immortalized by DN p53 resulted in increased levels of several procaspases and enhanced sensitivity of aB-crystallin -/-KO MEFs to chemotherapy. Third, silencing aB-crystallin in human MDA-MB-468 triple-negative breast cancer cells, which lack Rb and express mutant p53, increased their sensitivity to chemotherapy compared to non-silencing controls. Importantly, this human triple-negative breast cancer cell line recapitulates several molecular abnormalities frequently observed in clinical triple-negative breast tumors: Rb loss, TP53 mutation, and aB-crystallin expression [9] [10] [11] [12] [13] 18] . Taken together, our results indicate that aB-crystallin inhibits caspase activation in cells primed for apoptosis by Rb inactivation and plays a key role in promoting cell survival in this context. Moreover, our findings point to aB-crystallin as a potential therapeutic target: aB-crystallin expression would be predicted to confer chemotherapy resistance, while inhibition of aB-crystallin activity or expression would be predicted to sensitize tumors to chemotherapy. Indeed, we have previously demonstrated that aB-crystallin expression in breast cancer was associated with resistance to neoadjuvant (pre-surgery) chemotherapy in women with invasive breast cancer [33] .
We also showed that aB-crystallin plays an essential role in oncogenic transformation by the combination of E1A-mediated Rb inactivation and p53 inhibition. Specifically, aB-crystallin -/-KO MEFs immortalized by a DN p53 construct are resistant to transformation by E1A, while wild-type MEFs are readily transformed by the combination of DN p53 and E1A. Consistent with their transformed phenotype, WT E1A DN p53 MEFs grow more rapidly than aB-crystallin -/-KO E1A DN p53 MEFs and are much more invasive. The growth-promoting effects of aBcrystallin in transformed WT E1A DN p53 MEFs were particularly striking given our observation that aB-crystallin inhibited cell growth and S-phase entry in MEFs immortalized by DN p53. These latter results suggest that aB-crystallin promotes dysregulated growth in the setting of E1A-induced Rb inactivation by opposing its Fig. 4 12 h, and caspase-3 activity was measured using a colorimetric assay and normalized to levels present in WT E1A DN p53 MEFs (mean ± SD, n = 3). *P \ 0.05 versus control WT E1A DN p53 MEFs apoptosis-sensitizing effects, rather than by augmenting its mitogenic actions. Intriguingly, the oncogenic actions of aB-crystallin appear to be context-dependent: deletion of aB-crystallin did not confer resistance to oncogenic transformation by the combination of H-RasV12 and DN p53 in MEFs. Our results suggest that aB-crystallin promotes oncogenic transformation in the setting of combined Rb and p53 inactivation by inhibiting caspase activation in cells primed for apoptosis by the accumulation of procaspases.
Our findings have important implications for triplenegative breast cancer, which frequently harbor TP53 mutations, Rb gene loss and/or reduced Rb expression, and aB-crystallin expression [9] [10] [11] [12] 18] . RB1 loss of heterozygosity was reported in 72 % of human breast cancers with a basal-like gene expression pattern [11] ; these basallike tumors are typically triple-negative by ER/PR/HER2 hormone receptor expression [13] . Moreover, enhanced p53 expression by immunohistochemistry, indicative of stabilization of the WT p53 protein by mutant p53 protein, is frequently observed in basal-like tumors with reduced Rb expression [12] . TP53 mutations also cooperate with Rb deletion to promote triple-negative mammary tumors in mice [34] . We recently reported that aB-crystallin is expressed in about half of basal-like breast tumors and promotes an invasive, apoptosis-resistant phenotype in breast epithelial cells [18] . Others have confirmed the association of aB-crystallin expression with poor outcomes and the basal-like/triple-negative subtype of breast cancer and described a similar oncogenic role for aB-crystallin in the pathogenesis of glioblastoma multiforme [16, 35, 36] . It is tempting to speculate that the observed role of aB-crystallin in suppressing caspase activation in setting of Rb inactivation and p53 inhibition might account for the frequent occurrence of these three molecular events (Rb loss, TP53 mutation, and aB-crystallin expression) in clinically aggressive triple-negative breast cancers, although it remains to be determined how frequently all three of these events occur in individual basal-like/triple-negative tumors. Nevertheless, our results suggest that aB-crystallin may represent a unique molecular target to enhance the vulnerability of these tumors to cytotoxic agents, a hypothesis we are actively exploring in murine models.
